VREX Stock Analysis: Buy, Sell, or Hold?
VREX - Varex Imaging Corporation Common Stock
$18.51
0.02 (0.11%)
▲
5d:
+0.11%
30d:
+72.67%
90d:
+82.72%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When VREX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VREX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VREX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.62
Based on 13.6% avg growth
INTRINSIC VALUE TODAY
$15.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VREX is currently trading at $18.51, which is considered extended relative to its 30-day fair value range of $10.14 to $17.10. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.9) compared to its historical average (12.0). At these levels, the market is pricing in 12.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VREX is in a uptrend. The price is currently testing key support at $18.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VREX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VREX is in a uptrend. The price is currently testing key support at $18.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VREX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.14 -
$17.10
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range (+8.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($18.93)
- NEUTRAL: PE elevated vs history but 12.2% growth expectation is conservative given 453% recent growth
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.14 -
$17.10
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.37
Resistance Level
$18.63
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.92
Wall Street Target
$18.93
(+2.2%)
Revenue Growth (YoY)
3.7%
Earnings Growth (YoY)
453.4%
Profit Margin
2.6%
Valuation Premium vs History
+12.2% premium
PE vs Historical
16.9 vs 12.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.2%
(market-implied from PE analysis)
1-Year Target
$20.77
(+12%)
2-Year Target
$23.30
(+26%)
3-Year Target
$26.14
(+41%)
3-Yr Target (if PE normalizes)
(PE: 17→12)
PE COMPRESSION
$18.54
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 23.2%)
$41.06
(+122%)
Base:
(SPY PE: 16.9, Growth: 23.2%)
$34.61
(+87%)
Bear:
(PE: 12.0, Growth: 23.2%)
$24.55
(+33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 34.89 | Current EPS (TTM): $0.53
Bull Case
$40.68
(+120%)
Analyst growth 100.0%, PE expands to 38.4
Base Case
$36.98
(+100%)
Market implied 100.0%, PE stable at 34.9
Bear Case
$12.57
(-32%)
Severe decline -20.0%, PE contracts to 29.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VREX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jay K Kunkel
SELL
4510 shares
2026-03-20
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
